Le Lézard
Classified in: Health
Subject: PER

Nomination Committee of Medivir appointed


STOCKHOLM, Oct. 28, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the Annual General Meeting in May 2022. 
According to an AGM resolution, the Nomination Committee 2021-2022 should consist of representatives of at least the three largest shareholders at the end of the third quarter of 2021 and the Chairman of the Board. 

Work on composing the Nomination Committee is now completed, and this year's Nomination Committee consists of: 
Karl Tobieson (Chairman), appointed by Linc AB
Jan Särlvik, appointed by Nordea Fonder
Anders Hallberg, appointed by HealthInvest Partners 
Uli Hacksell, Chairman of the Board, Medivir AB

The Annual General Meeting of Medivir will be held on Thursday May 5, 2022.

For further information, please contact:
Magnus Christensen, interim CEO and CFO
Phone: +46 (0)8 5468 3100
E-mail: magnus.christensen@medivir.com    

About Medivir

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.  
Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/medivir/r/nomination-committee-of-medivir-appointed,c3442902

The following files are available for download:

https://mb.cision.com/Main/652/3442902/1488188.pdf

Press release (PDF)

SOURCE Medivir


These press releases may also interest you

at 08:14
The Board of Directors for Integrated Services for Behavioral Health (ISBH) announced today, Ms. Samantha Shafer, LISW-S will be the next CEO of the multi-county nonprofit.  Ms. Shafer, a highly experienced leader in behavioral health services in...

at 08:13
Pathway Health Corp. (formerly Colson Capital Corp.) ("Pathway" or the "Company") is pleased to announce that it has entered into a Service Agreement (the "Agreement") with Canntab Therapeutics Limited ("PILL"), a Canadian biopharmaceutical company...

at 08:10
National Resilience, Inc. (Resilience), a technology focused manufacturing company dedicated to broadening access to complex medicines, today announced the acquisition of SwiftScale Biologics, a San Leandro, California-based company developing...

at 08:10
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced it has ranked first in Boston Globe's 2021 Top Places to Work in the "Largest Employer" category. This is the seventh consecutive year that Alnylam has been named...

at 08:10
Medexus Pharmaceuticals Inc. ("Medexus" or the "Company") and medac GmbH ("medac") announced that medac clarified with FDA details with regard to the projected NDA resubmission of treosulfan, an alkylating agent...

at 08:07
CoreLink, LLC, a leading designer and manufacturer of spinal implant systems, today announced the commercial launch and 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the CoreLink CentraFixtm Midline Fixation System....



News published on 28 october 2021 at 11:12 and distributed by: